

F. No. ND/CT/21/000090
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

19 6 DEC 2021

To,

M/s Bayer Pharmaceuticals Pvt. Ltd.,
Bayer House, Central Avenue, Hiranandani Estate,
Thane, Maharashtra (India) - 400607

Subject:- Permission to conduct clinical study entitled, "A single-arm, open-label Phase 4 study of Darolutamide in addition to standard androgen deprivation therapy for participants in India with high-risk non-metastatic castration-resistant prostate cancer(nmCRPC)" -- regarding.

Sir,

With reference to your application no. ND/CT04/FF/2021/28855 dated 12.11.2021, please find enclosed herewith the permission in **Form CT-06, No. CT/ND/203/2021** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019** granted based on evaluation in consultation with Subject Expert Committee (SEC).

This permission is subject to the conditions, as mentioned below.

Yours faithfully



(Dr. V. G. Somani)
Central Licensing Authority

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of

receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) **Firm is required to submit the sample size justification to CDSCO.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL
NEW DRUG**

The Central Licensing Authority hereby permits M/s Bayer Pharmaceuticals Pvt. Ltd., Bayer House, Central Avenue, Hiranandani Estate, Thane, Maharashtra (India) - 400607 Tele No.: 912225311234 FAX: 912225455063 to conduct clinical trial of the investigational new drug as per Protocol No.: 21707 Version No. 01 Protocol Date 28-SEP-2021 in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or Investigational New Drug:	Darolutamide 300 mg Film-coated tablets	
Therapeutic class:	Androgen Receptor Antagonist	
Dosage form:	Tablets	
Composition:	Each film coated tablet contains- Darolutamide 300mg	
Indications:	For treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)	
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
01	Dr. Gopichand Mamillapalli, 33-25-33, CH. City Cancer Centre Venkata Gopala Krishnaiah Street, Suryarao Pet, Vijaywada Andhra Pradesh – 520002	Institutional Ethics Committee, HCG Curie City Cancer Centre, no 44-1-1/3, Padavalarevu, Gunadala, Vijaywada Andhra Pradesh – 520004 ECR/121/Inst/ AP/2013/RR-19
02	Dr. Aseem Kumar Samar Bhagwan Mahaveer Cancer Hospital and Research Centre, Jawahar Lal Nehru Marg Jaipur Rajasthan - 302017	Institutional Ethics Committee Bhagwan Mahaveer Cancer Hospital and Research Centre, Jawahar Lal Nehru Marg, Jaipur, Rajasthan – 302017 ECR/19/Inst/ RJ/2013/RR-20
03	Dr. Chandan K Das Post Graduate Institute of Medical Education & Research (PGIMER), Sector-12, Department of Radiotherapy and Oncology, Chandigarh – 160012	Institutional Ethics Committee, Room no. 6006, 6 th Floor, Research Block B, Post Graduate Institute of Medical Education & Research (PGIMER), Sector- 12, Chandigarh Chandigarh – 1600 12 ECR/25/Inst/ CH/2013/RR-20

04	Dr. Rajeev Sood Room No 414, Admin block, Dr. RML Hospital, Type III, Connaught Place, New Delhi- 110001.	Institutional Ethics Committee Dr. RML Hospital and PGIMER, New Delhi. ECR/913/Inst/ UP/2017/RR-20
05	Dr. Amit Joshi Professor, Medical Oncology Department, Room no 1105, 3 rd floor, Homi Bhabha Block, TATA Memorial Hospital, Dr. Ernest Borges Road, Parel, Mumbai, Maharashtra – 400012	Institutional Ethics Committee-I, TATA Memorial centre, Dr. Ernest Borges Road, Parel, Mumbai, Maharashtra – 400012 ECR/170/Inst/ MH/2013/RR-19
06	Dr. Sudhir Rawal Rajiv Gandhi Cancer Institute and Research Centre , Sector-5 Rohini, New Delhi– 110085.	Institutional Review Board, Rajiv Gandhi Cancer Institute and Research Centre , Sector-5, Rohini, New Delhi – 110085 ECR/10/Inst/ DC/2013/RR-19
07	Dr. Sudeep Das Netaji Subhash Chandra Bose Cancer Hospital, 3081 Nayabad, New Garia, Kolkata – 700094 West Bengal	Ethics Committee of Netaji Subhash Chandra Bose Cancer Hospital, 3081 Nayabad, New Garia, Kolkata – 700094 West Bengal. ECR/286/Inst/ WB/2013/RR-19
08	Dr Giri Gurulingaiah Venkata Asst Professor of Medical Oncology, Room no 308, 3 rd Floor, OPD block, Victoria Hospital, Bangalore Medical college and Research Institute, K.R. Road, Fort, Bangalore-560002, Karnataka	Ethics Committee of Bangalore Medical College and Research Institute K.R Road, Fort, Bangalore Karnataka – 56000 ECR/302/Inst/KA/2013/RR-20
09	Dr Velavan Kandappan Erode Cancer Centre, 1/393, Velavan Nagar, Near Chintamani Petrol bunk, Perundurai Road, Thindal Medu, Thindal, Erode – 638012, Tamil Nadu	Institutional ethics Committee Erode Cancer Centre, 1/393, Velavan Nagar, Near Chintamani Petrol bunk, Perundurai Road, Thindal Medu, Thindal, Erode – 638012, Tamil Nadu ECR/319/Inst/TN/2013/RR-19
10	Dr Smita Kayal Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER), JIPMER campus Road, Gorimedu, Puducherry- 605006	Institutional Ethics Committee, 1 st Floor, Admin Building, JIPMER, Gorimedu, Puducherry- 605006 ECR/342/Inst/PY/2013/RR-19

11	Dr Rajendra Singh Arora Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, 52/B, Shankar Nagar, Main Road, Amravati Maharashtra – 446001, Maharashtra	Amravati Ethics Committee, Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, 52/B, Shankar Nagar, Main Road, Amravati Maharashtra – 446001 ECR/432/Inst/MH/2013/RR-19
12	Dr Haresh KP Rom No. 133, Dr Bhim Rao Ambedkar Institute of Rotary Cancer Hospital (Dr. BRA IRCH), All India Institute of Medical Sciences, New Delhi -110029	Institute Ethics Committee, Room No. 102, Old O.T. Block, All India Institute of Medical Sciences, Ansari Nagar, New Delhi -110029 ECR/538/Inst/DL/2014/RR-20

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.



(Dr. V. G. Somani)
Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi

Date:

16 DEC 2021

